Published in Eur J Pharmacol on March 03, 1994
To ingest or rest? Specialized roles of lateral hypothalamic area neurons in coordinating energy balance. Front Syst Neurosci (2015) 0.85
Characterization and distribution of binding sites for a new neurotensin receptor antagonist ligand, [3H]SR 48692, in the guinea pig brain. J Pharmacol Exp Ther (1995) 0.75
Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 4.53
Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) (1997) 2.31
Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci U S A (1993) 2.13
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol (2003) 2.12
Adrenal steroid receptors and actions in the nervous system. Physiol Rev (1986) 2.07
In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist. Eur J Pharmacol (1993) 1.98
Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J (1995) 1.93
The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J Biol Chem (1998) 1.84
Neurotensin and neurotensin receptors. Trends Pharmacol Sci (1999) 1.71
Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci (1995) 1.68
Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett (1993) 1.62
Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem (1996) 1.60
A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. Life Sci (1992) 1.56
An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem (1995) 1.54
Cannabinoid-receptor expression in human leukocytes. Eur J Biochem (1993) 1.53
Subcellular localization of peripheral benzodiazepine receptors on human leukocytes. Lab Invest (1994) 1.50
Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett (1993) 1.48
Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn Schmiedebergs Arch Pharmacol (1995) 1.43
Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) (1996) 1.40
The CCN family: a new class of inflammation modulators? Biochimie (2010) 1.37
DNA intercalating compounds as potential antitumor agents. 2. Preparation and properties of 7H-pyridocarbazole dimers. J Med Chem (1980) 1.34
Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol (1996) 1.32
Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett (1996) 1.32
Neurotensin: specific binding to synaptic membranes from rat brain. Proc Natl Acad Sci U S A (1977) 1.32
Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci (1983) 1.31
The immunosuppressant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae. Mol Cell Biol (1996) 1.30
Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest (1993) 1.28
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest (1996) 1.28
Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies. Life Sci (1983) 1.25
Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta (1996) 1.23
Effects of neurotensin on isolated intestinal smooth muscles. Eur J Pharmacol (1978) 1.23
Involvement of peripheral benzodiazepine receptors in the protection of hematopoietic cells against oxygen radical damage. Blood (1996) 1.21
Activation of phosphatidylinositol turnover by neurotensin receptors in the human colonic adenocarcinoma cell line HT29. FEBS Lett (1986) 1.19
In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol (1998) 1.18
Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: anatomical and subcellular distribution. Brain Res Bull (1987) 1.17
SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci (1995) 1.16
Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry (2004) 1.16
Regulation of amino acid transport in the liver. Emergence of a high affinity transport system in isolated hepatocytes from fasting rats. J Biol Chem (1979) 1.16
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int (2007) 1.14
Purification and characterization of a novel neurotensin-degrading peptidase from rat brain synaptic membranes. J Biol Chem (1986) 1.14
Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharmacol Exp Ther (1998) 1.14
Purification and characterization of the human SR 31747A-binding protein. A nuclear membrane protein related to yeast sterol isomerase. J Biol Chem (1997) 1.13
Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther (1997) 1.12
Blockade of 12-lipoxygenase expression protects cortical neurons from apoptosis induced by beta-amyloid peptide. Cell Death Differ (2004) 1.11
Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer (1999) 1.10
Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci (1996) 1.10
Neurotensin binding to extraneural and neural receptors: comparison with biological activity and structure--activity relationships. Mol Pharmacol (1980) 1.10
Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett (1995) 1.10
Isolation of a tridecapeptide from bovine intestinal tissue and its partial characterization as neurotensin. J Biol Chem (1976) 1.09
Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem (1996) 1.09
Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther (1996) 1.08
Electrophysiological and pharmacological characterization of peripheral benzodiazepine receptors in a guinea pig heart preparation. Life Sci (1984) 1.08
Autoradiographic localization of glucocorticosteroid and progesterone binding sites in the human post-mortem brain. J Steroid Biochem (1986) 1.08
Preparation of a pure monoiodo derivative of the bee venom neurotoxin apamin and its binding properties to rat brain synaptosomes. J Biol Chem (1982) 1.07
Distribution profile and properties of peripheral-type benzodiazepine receptors on human hemopoietic cells. Life Sci (1993) 1.06
Effects of neurotensin on intestinal smooth muscle: application to the study of structure-activity relationships. Ann N Y Acad Sci (1982) 1.05
Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. J Neurochem (1995) 1.04
The chemokine stromal cell-derived factor-1/CXCL12 activates the nigrostriatal dopamine system. J Neurochem (2007) 1.04
Multiple benzodiazepine receptors: evidence of dissociation between anticonflict and anticonvulsant properties by PK 8165 and PK 9084 (two quinoline derivatives). Life Sci (1981) 1.04
Pharmacology and biochemistry of neurotensin receptors. Rev Clin Basic Pharm (1987) 1.04
Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release. Neuroscience (2009) 1.04
Labelling of "peripheral-type" benzodiazepine binding sites in the rat brain by using [3H]PK 11195, an isoquinoline carboxamide derivative: kinetic studies and autoradiographic localization. J Neurochem (1983) 1.03
Identification of residues involved in neurotensin binding and modeling of the agonist binding site in neurotensin receptor 1. J Biol Chem (2000) 1.03
Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci (1996) 1.03
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties. Neuropharmacology (1985) 1.02
Neurotensin stimulates inositol trisphosphate-mediated calcium mobilization but not protein kinase C activation in HT29 cells. Involvement of a G-protein. Biochem J (1989) 1.01
Met-195 of the cholecystokinin-A receptor interacts with the sulfated tyrosine of cholecystokinin and is crucial for receptor transition to high affinity state. J Biol Chem (1998) 1.00
Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-(1-methylpropyl)-3 isoquinolinecarboxamide. II. In vivo studies. Life Sci (1983) 1.00
In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes. J Pharmacol Exp Ther (1994) 1.00
Are antihistamines sedative via a blockade of brain H1 receptors? J Pharm Pharmacol (1979) 1.00
Preparation of neurotensin selectively iodinated on the tyrosine 3 residue. Biological activity and binding properties on mammalian neurotensin receptors. Biochem Biophys Res Commun (1984) 1.00
Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology (1999) 0.99
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--I. Anticonvulsant properties. Neuropharmacology (1985) 0.98
Electrophysiological and pharmacological evidence that peripheral type benzodiazepine receptors are coupled to calcium channels in the heart. Life Sci (1985) 0.98
Chemokine network in the nervous system: a new target for pain relief. Curr Med Chem (2008) 0.98
The amino acid sequence of radioimmunoassayable neurotensin from bovine intestine. J Biol Chem (1978) 0.98
Synthesis and characterization of neurotensin analogues for structure/activity relationship studies. Acetyl-neurotensin-(8--13) is the shortest analogue with full binding and pharmacological activities. Eur J Biochem (1982) 0.98
Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol (2001) 0.97
Identification of the receptor subtype involved in the analgesic effect of neurotensin. J Neurosci (1999) 0.97
Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors. Eur J Pharmacol (1993) 0.97
Role of tachykinins in castor oil diarrhoea in rats. Br J Pharmacol (1997) 0.97
Neurotensin metabolism in various tissues of central and peripheral origins: ubiquitous involvement of a novel neurotensin degrading metalloendopeptidase. Biochimie (1988) 0.97
Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities. Biochem Biophys Res Commun (1999) 0.97
Biochemical characterization of the interaction of three pyridazinyl-GABA derivatives with the GABAA receptor site. Brain Res (1986) 0.96
Distribution of neurotensin binding sites in rat brain: a light microscopic radioautographic study using monoiodo [125I]Tyr3-neurotensin. Neuroscience (1987) 0.96
Neurotensin-mediated inhibition of cyclic AMP formation in neuroblastoma N1E115 cells: involvement of the inhibitory GTP-binding component of adenylate cyclase. Mol Pharmacol (1986) 0.95
The rat beta 3-adrenergic receptor gene contains an intron. FEBS Lett (1993) 0.95
Effect of the nonpeptide neurotensin antagonist, SR 48692, and two enantiomeric analogs, SR 48527 and SR 49711, on neurotensin binding and contractile responses in guinea pig ileum and colon. J Pharmacol Exp Ther (1994) 0.95
Inactivation of neurotensin by rat brain synaptic membranes. Cleavage at the Pro10-Tyr11 bond by endopeptidase 24.11 (enkephalinase) and a peptidase different from proline-endopeptidase. J Neurochem (1984) 0.95
Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur J Pharmacol (1998) 0.95
Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor. Eur J Pharmacol (2000) 0.95